Effect observation of CT guided125I particle implantation combined with bronchial artery infusion chemotherapy and embolization in the treatment of advanced non-small cell lung cancer
LIN Hui SU Xiang-hua
Department of Respiration,Mindong Hospital Affiliated to Fujian Medical University,Fujian Province,Fu′an 355000, China
Abstract：Objective To explore the clinical efficacy and safety of CT guided125I particle implantation combined with bronchial artery infusion chemotherapy and embolization in the treatment of advanced non-small cell lung cancer. Methods Altogether 70 cases ofⅢb-Ⅳstage non-small cell lung cancer who were treated in Department of Respiration in our hospital from May 2012 to May 2014 were selected and divided into the experiment group (34 cases)and the control group(36 cases)according to the different treatment methods.The experiment group was treated with CT125I guided particle implantation combined with bronchial artery infusion chemotherapy and embolization,and the control group was treated with bronchial artery infusion chemotherapy and embolization.For all the patients,Gemcitabine combined with Cisplatin chemotherapy was taken as the chemotherapy protocol and CT examinations and follow-up at postoperative 1,3 and 6 months were made for observation of the total effective rate and the incidence rate of adverse reactions.Results The near-term total effective rate of the experimental group was 76.47%,which was higher than that of the control group(50.00%),with significant difference(P＜0.05).The incidence rate of pneumothorax,hemoptysis,chest pain in the experimental group was higher than that in the control group,with significant difference(P＜0.05).There was no significant difference between the two groups in the incidence rate of fever and bone marrow suppression (P＞0.05). All adverse reactions were light and could be controlled.Conclusion As a safe and minimally-invasive method,application of125I particle implantation combined with bronchial artery infusion chemotherapy and embolization has significant near-term effect in the treatment of advanced non-small cell lung cancers.
Chaft JE，Rekhtman N，Sima CS，et al.PhaseⅡ study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers[J].Cancer Chemother Pharmacol，2013，72（4）：931-934.
[15]
Neg S，Ellis RJ，Merrick GS，et al.American Brachytherapy Society ecommendation for reporting morbidity after prostate brachytherapy[J].In J Radiat Biol Phys，2002，54（2）：462-470.
京公网安备 11010502046607号